PMV Pharmaceuticals, Inc. (PMVP)
| Market Cap | 756.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.68M |
| Shares Out | 45.57M |
| EPS (ttm) | -1.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,432,203 |
| Open | 15.39 |
| Previous Close | 13.21 |
| Day's Range | 15.09 - 18.12 |
| 52-Week Range | 11.44 - 37.32 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 49.98 (+201.3%) |
| Earnings Date | May 13, 2022 |
About PMVP
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and change...
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for PMVP stock is "Buy." The 12-month stock price forecast is 49.98, which is an increase of 201.27% from the latest price.
News
PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of C...
CRANBURY, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-ag...
PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights
CRANBURY, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapi...
PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO)...
CRANBURY, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
CRANBURY, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...
PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference
CRANBURY, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...
PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day
CRANBURY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...
PMV Pharma Announces Changes to its Board of Directors
CRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...
PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference
CRANBURY, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...
PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
CRANBURY, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule therapies designe...
PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
CRANBURY, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...
PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
CRANBURY, N.J., Aug. 13, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule, tumor-agnostic t...
PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference
CRANBURY, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...
PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights
CRANBURY, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...
PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference
CRANBURY, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapi...
PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for ...
CRANBURY, N.J., April 10, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...
PMV Pharma Strengthens Board of Directors with Appointment of Dr. Charles Baum
CRANBURY, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...
PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American Association for Cancer Researc...
CRANBURY, N.J., March 10, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...
PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
CRANBURY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic thera...
PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board
CRANBURY, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...
PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference
CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...
PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Target...
CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
CRANBURY, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therap...
Andreas Halvorsen Jumps on PMV Pharmaceuticals
Andreas Halvorsen (Trades, Portfolio) revealed he established a new position in PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Sept. 25, according to GuruFocus' Real-Time Picks.
PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option ...
CRANBURY, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targetin...
PMV Pharmaceutical's stock nearly doubles in its debut
PMV Pharmaceuticals Inc.'s stock debuted with a bang Friday, as the the stock opened at nearly double the initial public offering price. The first trade was at $35.00 at 12:09 p.m.